Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Aligning, Appraising, and Simplifying Scientific Data Strengthens Promotional Claims

Pharmaceutical companies must convert complex scientific data into clear promotional materials that comply with regulatory standards and effectively communicate with healthcare professionals and patients. This involves evaluating data alignment, assessing evidence quality, and simplifying messaging. Missteps can result in legal and financial repercussions.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Vodori on MarketScale.

By Annalise Ludtke ·
Share
Aligning, Appraising, and Simplifying Scientific Data Strengthens Promotional Claims

Key takeaways

01

Evaluate new scientific data for alignment with drug's indication and regulatory constraints.

02

Thorough appraisal of evidence quality is crucial for credible claims.

03

Clear communication requires simplifying complex data while maintaining accuracy.

The pharmaceutical industry faces the challenge of converting complex medical and scientific information into clear, effective promotional claims. This process is critical as it balances the need for accurate scientific communication with the requirement for impactful marketing. The stakes are high, as promotional materials must adhere to stringent regulatory standards while also appealing to healthcare professionals and patients. Missteps can lead to significant legal and financial repercussions, making it essential for pharmaceutical companies to get this process right.

Missteps can lead to significant legal and financial repercussions, making it essential for pharmaceutical companies to get this process right.

How do teams navigate the complexities of transforming dense scientific data into clear, approvable promotional material without losing accuracy or impact?

On this episode of Amend & Progress, hosted by Annalise Ludtke, Joe DiCapite, Director of Strategy for the UK and Europe at Vodori, delves into the intricate process of converting medical and scientific information into claims. Together, they discuss the challenges, best practices, and the importance of inter-team collaboration in ensuring successful outcomes.

Key Discussion Points

  • Ensure appropriateness: Teams must first evaluate whether new scientific data aligns with their drug's indication and regulatory constraints to determine its suitability for promotional claims.
  • Assess evidence quality: A thorough appraisal of the evidence's quality, including study design and statistical significance, is crucial to ensure the claim's credibility and withstand scrutiny from competitors and regulators.
  • Effective communication: Transforming complex scientific data into clear, impactful, and accurate claims requires simplifying jargon while maintaining precision, tailored to different audience needs, and considering the overall impression of the promotional material.

Joe DiCapite brings extensive experience in medical writing, medical affairs, and marketing. His background includes a strong foundation in the pharmaceutical industry, with a focus on critical appraisal and compliance processes. His expertise spans both the strategic and operational aspects of converting scientific data into promotional claims, making him a valuable voice in this field.

Vodori

Part of this channel

Vodori

Faster market access through compliant life science content review.

Visit the channel

About the author

AL
Annalise Ludtke

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Pharma M&A surges on a single day: KKR's $5.7B Integer deal, Curium's $8B Lantheus buy, and AstraZeneca's blocked megamerger signal a restructuring market

Pharma M&A surges on a single day: KKR's $5.7B Integer deal, Curium's $8B Lantheus buy, and AstraZeneca's blocked megamerger signal a restructuring market

Three significant transactions occurred in the pharmaceutical and medtech sectors on August 3, highlighting a split M&A market. While mid-market buyouts such as KKR's acquisition of Integer Holdings and Curium's purchase of Lantheus proceeded, larger megamergers like AstraZeneca's faced obstacles. This suggests a trend towards restructuring within the industry.

  • 01KKR acquired Integer Holdings for $5.7 billion.
  • 02Curium purchased Lantheus in an $8 billion deal.
  • 03AstraZeneca's megamerger attempt was blocked.

Aug 3, 2026

CMS centralizes AI and interoperability under a new Office of Health Technology and Products

CMS centralizes AI and interoperability under a new Office of Health Technology and Products

The Centers for Medicare & Medicaid Services (CMS) has established the Office of Health Technology and Products to integrate AI, interoperability, and digital strategies. This new office aims to enhance efficiency across Medicare, Medicaid, and CHIP programs. By centralizing these efforts, CMS seeks to improve healthcare delivery and outcomes.

  • 01The CMS has launched a new office focusing on AI and interoperability.
  • 02The Office of Health Technology and Products will support Medicare, Medicaid, and CHIP programs.
  • 03Centralizing digital strategies aims to improve healthcare delivery and outcomes.

Aug 1, 2026

CMS centralizes health tech authority in new office covering AI, interoperability, and claims modernization

CMS centralizes health tech authority in new office covering AI, interoperability, and claims modernization

The Centers for Medicare & Medicaid Services (CMS) has established a new Office of Health Technology and Products. This office assumes over 90 responsibilities to lead federal health IT strategy, focusing on areas like AI, interoperability, and claims modernization.

  • 01CMS's new office centralizes health tech authority, focusing on AI and interoperability.
  • 02The office takes on over 90 responsibilities to modernize claims processes.
  • 03CMS aims to lead federal health IT strategy with its new dedicated office.

Aug 1, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

JD
Joe DiCapite

Director of Strategy for the UK and Europe

Vodori

Joe DiCapite brings extensive experience in medical writing, medical affairs, and marketing. His background includes a strong foundation in the pharmaceutical industry, with a focus on critical appraisal and compliance processes. His expertise spans both the strategic and operational aspects of converting scientific data into promotional claims.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512